AgeX Therapeutics Presents at the Rodman & Renshaw Global Investment Conference
September 09 2019 - 07:00AM
Business Wire
AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a
biotechnology company focused on therapeutics for human aging,
announced that founder and CEO Michael D. West, Ph.D. is presenting
at the 21st Annual Rodman & Renshaw Global Investment
Conference at the New York Palace Hotel in New York City. Dr.
West’s presentation will take place on Monday, September 9, 2019 at
8:20 a.m. EDT.
Dr. West and the company’s CFO, Russell Skibsted, will be
available for meetings on-site at the conference and elsewhere in
New York City, on Monday, September 9 and Tuesday, September 10.
Meetings with them may be scheduled by contacting Bill Douglass at
(646) 504-0890, bill@gothamcomm.com.
A copy of the presentation will be made available on the
Investors section of the company’s website at www.agexinc.com.
About AgeX Therapeutics
AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on
developing and commercializing innovative therapeutics for human
aging. Its PureStem® and UniverCyte™ manufacturing and
immunotolerance technologies are designed to work together to
generate highly defined, universal, allogeneic, off-the-shelf
pluripotent stem cell-derived young cells of any type for
application in a whole host of diseases with a high unmet medical
need. AgeX has two preclinical cell therapy programs: AGEX-VASC1
(vascular progenitor cells) for tissue ischemia and AGEX-BAT1
(brown fat cells) for Type II diabetes. AgeX’s revolutionary
longevity platform named induced Tissue Regeneration (iTR™) aims to
unlock cellular immortality and regenerative capacity to reverse
age-related changes within tissues. AGEX-iTR1547 is an iTR-based
formulation in preclinical development. HyStem® is AgeX’s delivery
technology to stably engraft PureStem cell therapies and slowly
release iTR molecules in the body. AgeX is developing its core
product pipeline for use in the clinic to extend human healthspan,
and is seeking opportunities to form licensing and partnership
agreements around its broad IP estate and proprietary technology
platforms for non-core clinical applications.
For more information, please visit www.agexinc.com or connect
with the company on Twitter, LinkedIn, Facebook, and YouTube.
Forward-Looking Statements
Certain statements contained in this release are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Any statements that are
not historical fact including, but not limited to statements that
contain words such as “will,” “believes,” “plans,” “anticipates,”
“expects,” “estimates” should also be considered forward-looking
statements. Forward-looking statements involve risks and
uncertainties. Actual results may differ materially from the
results anticipated in these forward-looking statements and as such
should be evaluated together with the many uncertainties that
affect the business of AgeX Therapeutics, Inc. and its
subsidiaries, particularly those mentioned in the cautionary
statements found in more detail in AgeX’s reports filed with the
Securities and Exchange Commissions (copies of which may be
obtained at www.sec.gov). Subsequent events and developments may
cause these forward-looking statements to change. AgeX specifically
disclaims any obligation or intention to update or revise these
forward-looking statements as a result of changed events or
circumstances that occur after the date of this release, except as
required by applicable law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190909005334/en/
Bill Douglass Gotham Communications, LLC bill@gothamcomm.com
(646) 504-0890
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Feb 2024 to Mar 2024
AgeX Therapeutics (AMEX:AGE)
Historical Stock Chart
From Mar 2023 to Mar 2024